Twin Lakes Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Twin Lakes Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500	Closed	-$119K	–	225
2025 Q4	$119K	Hold	1,500	–	–	0.05%	100
2025 Q3	$98.1K	Hold	1,500	–	–	0.05%	105
2025 Q2	$59.3K	Hold	1,500	–	–	0.04%	123
2025 Q1	$45.3K	Hold	1,500	–	–	0.03%	129
2024 Q4	$52.4K	Hold	1,500	–	–	0.03%	139
2024 Q3	$60.1K	Hold	1,500	–	–	0.04%	131
2024 Q2	$71.5K	Hold	1,500	–	–	0.05%	118
2024 Q1	$65K	Hold	1,500	–	–	0.04%	126
2023 Q4	$75.9K	Hold	1,500	–	–	0.05%	114
2023 Q3	$68K	Hold	1,500	–	–	0.05%	118
2023 Q2	$61.5K	Hold	1,500	–	–	0.04%	125
2023 Q1	$53.6K	Hold	1,500	–	–	0.04%	128
2022 Q4	$56.7K	Hold	1,500	–	–	0.04%	130
2022 Q3	$66K	Buy	+1,500	New	+$63.2K	0.05%	123
2022 Q2	–	Sell	-1,500	Closed	-$56K	–	216
2022 Q1	$56K	Hold	1,500	–	–	0.03%	149
2021 Q4	$46K	Hold	1,500	–	–	0.02%	165
2021 Q3	$50K	Hold	1,500	–	–	0.03%	152
2021 Q2	$60K	Hold	1,500	–	–	0.03%	126
2021 Q1	$67K	Buy	+1,500	New	+$83.7K	0.04%	116

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Lakes Capital Management's IONS Position: Q1 2026 in Review

Twin Lakes Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 1,500 shares — an estimated $119K sold.

Twin Lakes Capital Management first reported a position in IONS in Q1 2021 and held it in 19 quarters. The position peaked at $119K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Twin Lakes Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Twin Lakes Capital Management sold 1,500 Ionis Pharmaceuticals shares in Q1 2026, an estimated $119K.
Twin Lakes Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2021 and held it in 19 quarters.
Twin Lakes Capital Management's Ionis Pharmaceuticals position peaked at $119K in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Twin Lakes Capital Management's 13F filing for Q1 2026, filed 18 May 2026.